

Please amend claims 1 and 16 as follows:

9/20 C17
1. (Amended) A conjugate of a non-immunogenic [toxin] RNase or therapeutic radionuclide and a cell-specific cytokine.

A3
15. (Amended) A kit comprising a conjugate of [onconase] an RNase and IL-15, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α .

16. (Amended) A method of treating a malignancy, comprising the steps of:

first administering to a subject having a malignancy a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α , and then administering to said subject a therapeutically effective amount of a conjugate of [onconase] an RNase and IL-15.

Please add the following claims:

14
17. A fusion protein as claimed in claim 7, wherein expression of said cell marker on said malignant cells is higher than expression of said cell marker on non-malignant cells.

16
21. A kit according to claim 15, wherein said RNase is onconase.